BIOAFFINITY TECHNOLOGIES INC (BIAF)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$15.27+19.48%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · BIAF
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Material Modification to Rights of Security Holders. To the extent required by
Other Events. On August 13, 2026, the Company issued a press release announcing the pricing of the Private Placement. A copy of this press release is filed hereto as Exhibit 99.1 and is incorporated herein by reference.
Entry into a Material Definitive Agreement. On August 12, 2026, bioAffinity Technologies, Inc. (the “ Company ”) entered into a securities purchase agreements (the “ Purchase Agreement ”) with an institutional investor (“the “ Purchaser ”) for the issuance and sale in a private placement (the “ Private Placement ”) of (i) pre-funded warrants (the “ Pre-Funded Warrants ”) at a purchase price of $0.4657 per Pre-Funded Warrant to purchase up to an aggregate of 8,462,027 shares (the “ Pre-Funded…
Unregistered Sales of Equity Securities. The information contained in
and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 30, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) received written notice (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous thirty…
Other Events. On July 22, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing a collaboration with Pictor, Inc., a targeted proteomic platform company, to support development and commercialization of the Company’s next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and chronic obstructive pulmonary disease (COPD). A copy of the press release is attached hereto as E…
Entry into a Material Definitive Agreement. On June 16, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), consummated a best efforts public offering (the “Offering”) of an aggregate of (i) 1,040,000 shares (the “Shares”) of common stock, par value $0.007 per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 2,960,000 shares of Common Stock (“Pre-Funded Warrants Shares”) in lieu of Shares. Each Share was sold at a…
and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this
The filing describes an amendment to the equity incentive compensation plan, not a management change.
and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this
Director — Robert Anderson and Roby Joyce: Robert Anderson and Roby Joyce decided not to stand for re-election to the Board.
and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this
Entry into a Material Definitive Agreement. Registered Direct Offering On October 8, 2025, bioAffinity Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue to the Purchasers in a registered direct offering (the “Offering”), 720,000 shares (the “Shares”) of the Company’s common stock, par value $0.007 per share (the “Common Stock”). The Offering c…
Entry into a Material Definitive Agreement. On September 29, 2025, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), consummated a best efforts public offering (the “Offering”) of an aggregate of (i) 1,047,694 shares (the “Shares”) of common stock, par value $0.007 per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 874,067 shares of Common Stock (“Pre-Funded Warrants Shares”) in lieu of Shares. Each Share was sold at…
Other Events The Company issued a press release announcing the pricing of the Offering on September 29, 2025. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein. The Company issued a press release announcing the closing of the Offering on September 30, 2025. A copy of the press release is filed herewith as Exhibit 99.2 and is incorporated by reference herein. As of the date of this Current Report on Form 8-K, after the closing of the Offering…
Material Modification to Rights of Security Holders. To the extent required by
Entry into a Material Definitive Agreement On September 2, 2025, bioAffinity Technologies, Inc, (the “Company”) and the holders of the warrants issued by the Company on May 7, 2025 (the “May 2025 Warrants”) and the warrants issued by the Company on August 13, 2025 (the “August 2025 Warrants”) agreed, effective as of August 12, 2025, to amend the Floor Price (as such term is defined in each of the May 2025 Warrants and the August 2025 Warrants) so as to increase it from $0.10 to $0.15. As a re…
Director — Gary Rubin: Gary Rubin resigned from the Board and from the Nominating and Corporate Governance Committee.
Other Events. On August 13, 2025, the Company issued a press release announcing the pricing of the Private Placement and Warrant Inducement. On August 14, 2025, the Company issued a press release announcing the closing of the Private Placement and Warrant Inducement. Copies of the press releases are furnished as Exhibit 99.1 and Exhibit 99.2, respectively to this Form 8-K. - 4 -
The Series B Preferred Stock, Warrants, and New Warrants are being issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.
and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this
Entry into a Material Definitive Agreement Private Placement Transaction On August 13, 2025, bioAffinity Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (“the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), (i) 990 shares of the Company’s newly designated Series B Convertible Preferred Stock, with a par value $0…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported in a Current Report on Form 8-K filed by bioAffinity Technologies, Inc. (the “Company”), on February 7, 2025, the Company received written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (December 23, 2024 through February 6, 2025), the Comp…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 27, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity of the Company of $1,439,404 as of March 31, 2025, as reported in the Company’s Quarterly Repo…
Importance-ranked changes since the prior daily snapshot.
Valuation fell by 20.2 points (from 35.9 to 15.7).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.